Similar results were obtained in a recent follow-up study by the same group, where dual-targeted oncolytic MVs able to bind murine stromal (via murine uPAR) and human cancer (via CD46) cells were engineered and shown to successfully infect and lyse the target cells in a species-specific fashion, both in vitro and in vivo, in colon (HT-29) cancer xenografts, leading to improved tumor suppression and overall survival compared to vehicle CD46-only targeted MVs [264] (Table 5, Figure 12). The gene discussed is CD46; the disease is cancer.